Palatin Technologies, Inc. (the "Company") (NYSE American:PTN), a biopharmaceutical company developing first-in-class ...

Technologies announced today that on April 10, NYSE American publicly announced and provided a notice to the company that NYSE ...

CRANBURY, N.J., April 10, 2025 /PRNewswire/ -- Palatin Technologies ... Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange (the "Panel").

NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Palatin ...

He served on the board of directors of Orna Therapeutics ... at 16:20 NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) NYSE American LLC ("NYSE American" or the ...

Health In Tech , an Insurtech platform company backed by third-party AI technology, is pleased to announce the appointment of a new independent director, Sanjay Shrestha, to the Company's Board of ...

Mr Graham serves on Recce’s Board of Directors and has invested in almost every ... Based in the US, Dr. Dunton, as the Director of Palatin Technologies, brings a wealth of experience with over three ...

Low dose bremelanotide arm stopped weight regain seen post tirzepatide treatment. Palatin Technologies, Inc. "Although the study was not designed to optimize weight loss, this 8-week study ...

CRANBURY, N.J. - Palatin Technologies, Inc. (NYSE American: PTN), a clinical-stage biotech company with a market capitalization of $17.22 million, has announced positive results from a Phase 2 ...

(RTTNews) - Palatin Technologies, Inc. (PTN), Thursday announced positive data from the Phase 2b BREAKOUT study of a melanocortin agonist in patients with diabetic Type 2 nephropathy. The six ...

Phase 1 SAD/MAD studies to include hypothalamic obesity patients. CRANBURY, N.J., March 31, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (PTN), a biopharmaceutical company developing first-in ...